The United States (US) Centers for Disease Control and Prevention (CDC) released an interim statement on May 23, 2018, regarding the safety of the antiretroviral drug, Dolutegravir (DTG).Dolutegravir is approved as part of the antiretroviral drug regimen for Post-exposure Prophylaxis (PEP) . The ...